STO Healthcare has introduced a range of pharmaceutical products from global manufacturer Bayer to the Maldivian market, marking a step toward expanding access to advanced medical treatments in the country.
The products were officially launched during a ceremony held at Hotel Jen Malé, accompanied by a training programme designed for healthcare professionals.
The event brought together senior health officials, local practitioners, and international experts, with a focus on sharing knowledge and introducing the latest innovations in medical treatment. Discussions covered several key areas, including cardiology, nephrology, endocrinology, internal medicine, and women’s health.
According to organizers, the newly introduced treatments are widely used in developed healthcare systems and are supported by scientific research demonstrating improved patient outcomes. The products have also been registered under the regulatory framework of the Maldives Food and Drug Authority, ensuring compliance with national standards.
The collaboration between STO Healthcare and Bayer is expected to contribute to ongoing efforts to strengthen the Maldives’ healthcare system by improving access to high-quality medicines and modern treatment options.
Officials noted that the partnership reflects a shared commitment to advancing healthcare services and supporting better health outcomes for the population.
